Aurinia Pharmaceuticals (AUPH) Retained Earnings (2015 - 2026)
Aurinia Pharmaceuticals posted quarterly Retained Earnings of -$880000.0 for Q1 2026, up 99.9% year-on-year from -$440212.1 in Q1 2025, and down 46.91% on a QoQ basis from -$599000.0 in Q4 2025.
Aurinia Pharmaceuticals (AUPH) has 12 years of Retained Earnings data on file, last reported at -$880000.0 in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings rose 99.9% year-over-year to -$880000.0; the trailing twelve-month figure through Mar 2026 stood at -$880000.0 (up 99.9% YoY), and the FY2025 full-year result was -$599000.0, up 99.94% from the prior year.
- Retained Earnings for Q1 2026 stood at -$880000.0, down from -$599000.0 in the prior quarter.
- Across five years, Retained Earnings topped out at -$599000.0 in Q4 2025 and bottomed at -$942.3 million in Q4 2023.
- The 5-year median for Retained Earnings is -$1.0 million (2023), against an average of -$317.6 million.
- Peak annual rise in Retained Earnings reached 99.94% in 2025, while the deepest fall reached 106835.13% in 2025.
- A 5-year view of Retained Earnings shows it stood at -$864.3 million in 2022, then decreased by 9.03% to -$942.3 million in 2023, then gained by 0.61% to -$936.6 million in 2024, then surged by 99.94% to -$599000.0 in 2025, then sank by 46.91% to -$880000.0 in 2026.
- The last three Retained Earnings figures came in at -$880000.0 (Q1 2026), -$599000.0 (Q4 2025), and -$749000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Aurinia Pharmaceuticals | 2.03 Bn | 1.65 Bn | 71.20 Mn | -880,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -880,000.00 |
| Dec 31, 2025 | -599,000.00 |
| Sep 30, 2025 | -749,000.00 |
| Jun 30, 2025 | -905,000.00 |
| Mar 31, 2025 | -913.23 Mn |
| Dec 31, 2024 | -936.57 Mn |
| Sep 30, 2024 | -938.00 Mn |
| Jun 30, 2024 | -859,000.00 |
| Mar 31, 2024 | -854,000.00 |
| Dec 31, 2023 | -942.32 Mn |
| Sep 30, 2023 | -947,000.00 |
| Jun 30, 2023 | -1.02 Mn |
| Mar 31, 2023 | -988,000.00 |
| Dec 31, 2022 | -864.30 Mn |
| Sep 30, 2022 | -1.53 Mn |
| Jun 30, 2022 | -1.85 Mn |
| Mar 31, 2022 | -793.75 Mn |
| Dec 31, 2021 | -852,000.00 |
| Sep 30, 2021 | -794,000.00 |
| Jun 30, 2021 | -672.55 Mn |
| Mar 31, 2021 | -625.54 Mn |
| Dec 31, 2020 | -805,000.00 |
| Sep 30, 2020 | -805,000.00 |
| Jun 30, 2020 | -805,000.00 |
| Mar 31, 2020 | -805,000.00 |
| Dec 31, 2019 | -472.48 Mn |
| Sep 30, 2019 | -805,000.00 |
| Jun 30, 2019 | -805,000.00 |
| Mar 31, 2019 | -805,000.00 |
| Dec 31, 2018 | -805,000.00 |
| Sep 30, 2018 | -805,000.00 |
| Jun 30, 2018 | -805,000.00 |
| Mar 31, 2018 | -805,000.00 |
| Dec 31, 2017 | -883,000.00 |
| Sep 30, 2017 | -894,000.00 |
| Jun 30, 2017 | -805,000.00 |
| Mar 31, 2017 | -805,000.00 |
| Dec 31, 2016 | -805,000.00 |
| Sep 30, 2016 | -805,000.00 |
| Jun 30, 2016 | -805,000.00 |
| Mar 31, 2016 | -805,000.00 |
| Dec 31, 2015 | 805,000.00 |
| Sep 30, 2015 | -805,000.00 |
| Jun 30, 2015 | -805,000.00 |
| Mar 31, 2015 | -805,000.00 |